Previous 10 | Next 10 |
home / stock / hls:cc / hls:cc news
The S&P/TSX Composite Index was down 234 points in late-morning trading on Friday, September 16. This would represent the third triple-digit decline over this trading week. Some of the worst-performing sectors included health care, information technology, and industrials. Today,...
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on September 22, 2022 Canada NewsWire TORONTO , Sept. 15, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and c...
HLS Therapeutics Announces Q2 Fiscal 2022 Financial Results Canada NewsWire Q2 2022 revenue of $15.5 million , Adjusted EBITDA of $6.2 million and cash from operations of $3.5 million . Total Vascepa prescriptions grew 88% year-over-year, reflecti...
HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan Canada NewsWire Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-la...
HLS Therapeutics to Host Q2 Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , July 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results o...
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan Canada NewsWire Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label ...
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in New Brunswick and with other Public Payors Canada NewsWire New Brunswick , Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will...
HLS Therapeutics Reports Annual Meeting Results Canada NewsWire TORONTO , June 17, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces vot...
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 22, 2022 Canada NewsWire TORONTO , June 15, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiov...
HLS Therapeutics to Present at the 2022 Jefferies Healthcare Conference Canada NewsWire TORONTO , June 1, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular...
News, Short Squeeze, Breakout and More Instantly...
HLS Therapeutics Inc. Company Name:
HLS:CC Stock Symbol:
TSXC Market:
HLS Therapeutics Inc. Website:
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust Canada NewsWire Total consideration of up to $45.75 million , which consists of upfront cash, sales-based milestone payments and DRI Healthcare's assumption of future mi...
A look at the top 10 most actives in Canada BlackBerry Limited (BB) rose 10.5% to $3.36 on volume of 12,209,225 shares Solstice Gold Corp. (SGC) fell 33.3% to $0.02 on volume of 11,588,936 shares HIGH INTEREST SAVINGS ACCOUNT FUND (HISA) fell 0.3% to $50.01 on volume of 10,628,355 shares ...
Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...